#USA #New Jersey #Pomerantz LLP #Nano-X Imaging #NNOX

Pomerantz Law Firm Files Class Action Against Nano-X Imaging

In a significant legal move, Pomerantz LLP has announced the filing of a class action lawsuit against Nano-X Imaging Ltd., a prominent player in the medical imaging sector. This lawsuit is aimed at protecting investors who bought Nano-X securities between March 31, 2025, and April 17, 2026—an interval during which several important operational misrepresentations allegedly occurred.

The lawsuit has been filed in the United States District Court for the District of New Jersey under docket number 26-cv-07062. It serves to represent a class made up of individuals and entities who acquired Nano-X securities during the specified period, excluding the defendants themselves. The primary objective of this legal action is to recover damages resulting from alleged violations of federal securities laws, particularly under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, in addition to Rule 10b-5.

According to Pomerantz, potential class members have until August 11, 2026, to request an appointment as Lead Plaintiff, thereby taking an active role in this litigation. Interested investors can obtain a copy of the Complaint through the Pomerantz Law Firm’s website and can reach out to Danielle Peyton via the proporcionate contact details for further discussion.

Overview of Nano-X Imaging

Nano-X Imaging Ltd. is known for its innovative technologies in the medical imaging realm, particularly its advanced tomographic imaging device that utilizes a digital X-ray source. The company operates alongside subsidiaries providing vital teleradiology services and developing AI applications tailored for medical purposes. Key to its operations are their manufacturing facilities, both self-owned and third-party, some of which produce crucial components for their X-ray products in locations like the Republic of Korea.

Throughout the class period, the senior executives of Nano-X consistently assured investors about the operational improvements the company was undertaking to scale up production effectively, responding to anticipated demand post-regulatory approvals in various regions. These reassurances often highlighted projected profitability and cost-effectiveness, alongside new partnerships that ostensibly indicated a robust operational strategy, providing an impression that the company was managing growth successfully.

However, the lawsuit alleges that these claims were unsubstantiated and misleading. It asserts that the company misrepresented the efficiency and scaling of its operations while overlooking critical issues like mounting operational expenses and a mismatch between production capabilities and market demand. This misalignment purportedly led to significant financial strain, increasing the likelihood of disruptive measures such as restructuring, which could further exacerbate the company’s financial instability.

The Unfolding Crisis

The situation took a downturn on April 20, 2026, when Nano-X released its Q4 financial results, revealing a staggering net loss of $33.4 million. This significant dip was partially due to a $17.5 million charge associated with asset impairment, stemming from a restructuring initiative aimed at realigning their production model to better meet current and future demand. Crucially, this announcement also included the resignation of the Chief Financial Officer, indicating deeper complications within the company's operational structure.

In light of these disclosures, there was a notable reaction in the stock market, with Nano-X’s shares experiencing a sharp decline—losing $0.695 per share, or nearly 25%, on the same day. This rapid decrease emphasized investors' growing concerns about the company’s financial health and operational integrity.

About Pomerantz LLP

Pomerantz LLP, with an extensive history in corporate law and securities legislation, is recognized as one of the premier entities representing victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. Established over eight decades ago by Abraham L. Pomerantz, the firm has a proven track record of securing billions in damages for class members in various high-stakes lawsuits. With offices in key financial centers globally, it remains committed to defending the rights of investors.

This class action represents an essential step for shareholders seeking justice and transparency from Nano-X Imaging Ltd., underscoring the critical nature of accountability in corporate governance.